Hyman DM, Willis T, Kummar S, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. J Clin Oncol 35, 2017 (suppl; abstr LBA2501).
CAR T-celtherapie bij kinderen en jongvolwassenen met B-ALL: real-world data komen overeen met studieresultaten
apr 2020